Key Takeaways:
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) plans to submit a New Drug Application to the U.S. Food and Drug Administration in the third quarter of 2026 for its anti-seizure medicine, azetukalner, after reporting positive Phase 3 data.
"The strong X-TOLE2 results have paved the way for us to submit an NDA to the FDA in the third quarter of 2026 and our commercial preparedness activities are well underway," Ian Mortimer, President and Chief Executive Officer of Xenon, said in a statement.
The company reported a first-quarter net loss of $102.3 million, or $1.17 per share, matching analyst estimates but wider than the $65.0 million loss from a year earlier. Revenue was zero, missing estimates of $15 million, compared to $7.5 million in the prior-year period which included milestone payments from its collaboration with Neurocrine Biosciences (NASDAQ: NBIX). The pivotal Phase 3 X-TOLE2 study showed a placebo-adjusted median seizure reduction of 42.7% for patients taking a 25 mg dose of azetukalner.
The planned regulatory submission significantly de-risks the path to market for azetukalner, which could become the only Kv7 potassium channel opener available for treating epilepsy. Xenon is well-capitalized for the process, reporting cash and marketable securities of $1.34 billion as of March 31, which it states is sufficient to fund operations into 2029.
Xenon’s operating expenses grew during the quarter, with research and development costs rising 45% year-over-year to $88.5 million. The increase was driven by the extensive Phase 3 program for azetukalner, which is also being studied for major depressive disorder and bipolar depression, and early-stage studies for its pain candidates, XEN1701 and XEN1120.
General and administrative expenses increased 25% to $23.8 million, primarily due to higher personnel costs and professional fees as the company prepares for potential commercialization.
The successful trial results and upcoming NDA filing shift the focus for Xenon from clinical development to regulatory execution and market preparation. Investors will now be watching for the formal submission to the FDA in Q3 2026, the primary catalyst for the company in the near term.
This article is for informational purposes only and does not constitute investment advice.
